Trozet Tablet

Letrozole
2.5mg
Fresenius Kabi pharmaceuticals
Pack size
Dispensing mode
Source
Agent
Retail Price

Indications

Trozet Tablet is used for: Breast cancer

Adult Dose

Oral Advanced or locally advanced breast cancer ; Adjuvant therapy for postmenopausal women with hormone receptor positive early breast cancer Adult: 2.5 mg once daily. Hepatic impairment: Reduce dose by 50% in patients with cirrhosis and severe hepatic impairment; recommended dose: 2.5 mg on alternate days.

Child Dose

Renal Dose

Administration

May be taken with or without food.

Contra Indications

Premenopausal women and children; hypersensitivity.

Precautions

Severe renal impairment; severe hepatic impairment; osteoporosis. Caution when driving or operating machinery. Lactation: not known if excreted in breast milk (for post-menopausal women)

Pregnancy-Lactation

Interactions

Plasma levels reduced by tamoxifen.

Adverse Effects

Side effects of Letrozole : Hot flushes, arthralgia, nausea, vomiting, fatigue, dizziness, headache, dyspepsia, constipation, diarrhoea, anorexia, alopoecia, increased sweating, rash, peripheral oedema, osteoporosis, musculoskeletal pain, vaginal irritation. Potentially Fatal: Thromboembolic events.

Mechanism of Action

Letrozole competitively binds to the heme group of aromatase, a cytochrome P450 enzyme which catalyzes conversion of androgen to oestrogen, leading to inhibition of the enzyme and a significant reduction in plasma oestrogen levels.

Note

Trozet 2.5mg Tablet manufactured by Fresenius Kabi pharmaceuticals. Its generic name is Letrozole. Trozet is availble in Nepal. Farmaco Nepal drug index information on Trozet Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Letrozole :